利伐沙班中国2019Q1业绩翻番，达5.6亿元；拜耳医药表现突出
1
2019年Q1，拜耳医药中国市场业绩7.76亿欧元，同比增长24%：
电话会议拜耳处方药全球总裁Stefan Oelrich 披露，拜耳目前当家品种利伐沙班（Xarelto）（拜瑞妥）2019年Q1在中国的销售业绩翻倍；利伐沙班Q1业绩为7500万欧元（约合人民币5.6亿元）；
索拉非尼（Nexavar）和瑞戈非尼（Stivarga）在中国也是快速放量，目前两者均进入医保；
老药硝苯地平（Adalat）、莫西沙星（Avelox）、阿卡波糖（Glucobay）仍然在中国显示出强烈需求。但是未来中国推行的仿制药4+7带量采购也会给原研品种带来不小挑战。
不过Stefan Oelrich 表示：非常满意中国市场业绩，2022年希望中国市场业绩突破30亿欧元。
2
2019年Q1，拜耳医药处方药业绩43.54亿欧元，同比增长5%；主要驱动因素是由于利伐沙班（Xarelto）、阿柏西普（Eylea）、中国市场表现抢眼。
3
拜耳医药TOP销售品种
4
附：
Pharmaceuticals increases sales and earnings
Sales of prescription medicines (Pharmaceuticals) rose by 5.3 percent (Fx & portfolio adj.) to 4.354 billion euros, buoyed by continuing strong development of the anticoagulant Xarelto™ and the eye medicine Eylea™ and significant overall growth in China. Sales of Xarelto™ advanced by 14.8 percent (Fx & portfolio adj.), mainly as a result of higher volumes in China, Japan and Europe. Sales of Eylea™ increased by 14.5 percent (Fx & portfolio adj.) thanks to higher volumes, with business developing particularly well in the United Kingdom, France and Germany.
Sales of the cancer drugs Nexavar™ and Stivarga™ and of the pulmonary hypertension treatment Adempas™ also increased by double digit percentages. Stivarga™ achieved the strongest percentage increase in sales, at 34.5 percent (Fx & portfolio adj.), primarily due to higher volumes in China and significantly improved business in the United States. Sales of Adempas™ rose by 12.9 percent (Fx & portfolio adj.) thanks to higher volumes in the United States and Europe. The 11.4 percent increase (Fx & portfolio adj.) in sales of Nexavar™ was driven by product launches in China in prior years along with volume increases, especially in Germany and Brazil. The 24.4 percent decline (Fx & portfolio adj.) in sales of the multiple sclerosis treatment Betaferon™/
Betaseron™ was again mainly attributable to intense competition in the United States.
EBITDA before special items of Pharmaceuticals rose by 6.9 percent (Fx adj. plus 10.0 percent) to 1.512 billion euros, primarily due to the very good development of business and lower cost of goods sold.
更多各大药企产品信息，关注药融数据。
参考：
NMPA/CDE；
药融数据，Pharnex Datamonitor；
相关公司公开披露；
https://www.investor.bayer.de/en/nc/news/investor-news/investor-news/bayer-strong-operational-start-to-the-year/；
https://www.investor.bayer.com/en/nc/events/live-events/q1-2019-conference-call/；等等。